Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, randomized trial of drug-eluting stents [sirolimus, paclitaxel] vs. bare metal stents for the reduction of restenosis in bypass grafts.

Next Previous
Trial Profile

Prospective, randomized trial of drug-eluting stents [sirolimus, paclitaxel] vs. bare metal stents for the reduction of restenosis in bypass grafts.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Sep 2011

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary) ; Sirolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
  • Focus Therapeutic Use
  • Acronyms ISAR-CABG

Most Recent Events

  • 12 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 05 Apr 2011 Results published at the 60th Annual Scientific Session of the American College of Cardiology.
  • 04 Jan 2011 Planned end date changed from 1 Mar 2010 to 1 Mar 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top